Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 7INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 6Myeloid 3Plasma cell 1

Conditions

Polycythemia Vera 3Myeloproliferative Disorders 3

Interventions

Azacitidine 68nilotinib 50Imatinib Mesylate 50ruxolitinib 42Dasatinib 25venetoclax 22Decitabine 20bosutinib 18asciminib 17Cytarabine 15ponatinib 10decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 9fludarabine 8Hydroxyurea 8navitoclax 6ON 01910 6sabatolimab 5pevonedistat 5mocetinostat 5luspatercept 5itacitinib 5imetelstat 5givinostat hydrochloride 5givinostat 5fludarabine phosphate 5avapritinib 5Mycophenolic Acid 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Aspirin × Myeloid × Clear all
NCT04182100 2025-09-15

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

PharmaEssentia Japan K.K.

Phase 2 Completed
29 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT06290765 2025-07-31

PV

PharmaEssentia

Phase 4 Not yet recruiting
70 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT06002490 2024-11-08

A Study to Evaluate P1101 in Japanese PV Patients

PharmaEssentia Japan K.K.

Phase 3 Completed
21 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡